Archive · 24 Jul 2026
Scribe Therapeutics surges 67% after $128.7M IPO
Scribe Therapeutics, a biotech company focused on gene therapies for heart diseases, recently had its initial public offering (IPO).
The company raised $128.7 million and its stock price surged by 67% on the first day of trading.
This means many investors are excited about the company's potential.
Scribe is working on treatments for heart and metabolic diseases, with a specific focus on atherosclerotic cardiovascular disease (ASCVD).
The company expects to share initial data from its trials in the first half of 2027.
However, Scribe has also reported significant financial losses, which is a concern for some investors.
Major backers include Eli Lilly & Co., Sanofi SA, Andreessen Horowitz, and Avoro Life Sciences Fund.
Scribe Therapeutics' stock surged 67% after raising $128.7 million in an upsized IPO.
The company sold 8.58 million shares at $25 each, giving it a market value of about $440.3 million.
Scribe focuses on gene-editing technologies for heart and metabolic diseases, particularly ASCVD.
Initial data from its trials is expected in the first half of 2027.
The company reported a net loss of $17.4 million for the three months ended March 31, 2024.
- Who
- Scribe Therapeutics Inc., Eli Lilly & Co., Sanofi SA, Andreessen Horowitz, Avoro Life Sciences Fund
- What
- Initial public offering (IPO) and subsequent stock surge
- When
- Friday, after raising $128.7 million in an upsized IPO on Thursday
- Where
- New York Stock Exchange
- Why
- Investor optimism in gene-editing technologies and potential market value
Investor Optimism
Financial Losses
Market Performance
Investor Optimism
Investors are optimistic about Scribe Therapeutics' potential in gene-editing technologies, leading to a 67% surge in stock price post-IPO.
Financial Losses
The company has reported significant net losses, raising concerns about its financial stability.
- Company
- Scribe Therapeutics Inc.
- IPO Price
- $15 per share
- Market Value
- $440.3 million
- Shares Sold
- 8.58 million
- Key Backers
- Eli Lilly & Co., Sanofi SA, Andreessen Horowitz, Avoro Life Sciences Fund
- Focus Area
- Gene-editing technologies for heart and metabolic diseases
- Expected Data Release
- First half of 2027
- Net Loss (Q1 2024)
- $17.4 million